ID   Hepc/2D6.39
AC   CVCL_B5W2
DR   cancercelllines; CVCL_B5W2
DR   Wikidata; Q111733389
RX   PubMed=11377097;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Genetic integration: Method=Transfection/transduction; Gene=HGNC; HGNC:2625; CYP2D6.
CC   Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P00552; Transposon Tn5 neo.
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
DI   NCIt; C3728; Hepatoblastoma
DI   ORDO; Orphanet_449; Hepatoblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0027 ! Hep-G2
SX   Male
AG   15Y
CA   Cancer cell line
DT   Created: 17-03-22; Last updated: 19-12-24; Version: 7
//
RX   PubMed=11377097; DOI=10.1016/S0887-2333(01)00011-x;
RA   Yoshitomi S., Ikemoto K., Takahashi J., Miki H., Namba M., Asahi S.;
RT   "Establishment of the transformants expressing human cytochrome P450
RT   subtypes in HepG2, and their applications on drug metabolism and
RT   toxicology.";
RL   Toxicol. In Vitro 15:245-256(2001).
//